Videos
Watch our experts break down complex topics and suggest ways to adjust your business. Gain clarity, step-by-step.
IRA Impacts on Patient Access
Ahead of Asembia 2023, Avalere experts discuss how the IRA and other regulatory changes will impact patient access and affordability.
Evidence and Value Under the Inflation Reduction Act
In our Outlook 2023 webinar, Avalere expert Michael Ciarametaro discussed how evidence generation requirements will differ under the Inflation Reduction Act (IRA.)
IRA Policy Changes: Planning for Life Sciences
The Inflation Reduction Act (IRA) brings some of the biggest changes affecting the pharmaceutical industry in the last decade. Avalere expert Megan West discusses how these shifts will impact pharmaceutical organizations and how Avalere can support in developing strategies to mitigate risk and identify opportunities across the product lifecycle.
Medicare Advantage and Part D Advance Notice: Proposed Payment Changes
Avalere expert Sean Creighton explains key policy changes proposed in the Advance Notice for Medicare Advantage and Part D Payment for Plan Year 2024.
The Future of Patient-Centric Value
Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.
Enhancing Oncology Model (EOM) Participation
Avalere expert Maddi Davidson discussed key EOM methods changes that will impact practice decision making.
Plan and Beneficiary Responses to IRA Policies
Avalere expert Rebecca Yip discussed plan and beneficiary responses to IRA policies during our 2023 Outlook webinar.
Innovative Partnerships in Medicare
In this video, Manoj Pawar, Chief Medical Officer of Mutual of Omaha, joins Avalere experts to discuss their recent partnership on a project that sought to identify innovative ways to use data to inform payer/provider partnerships in the Medicare program.
2022 Midterm Elections Recap: What’s Next for Healthcare Policy?
Join Avalere experts Elizabeth Carpenter and Matt Kazan for a discussion on the 2022 midterm election results and what to watch for future healthcare legislation.
RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Patient-Centered Value Frameworks
Avalere experts will discuss patient-centric value frameworks, their utility to different stakeholders, and how they can drive the transformation to a patient-centered, equitable health system at the AMCP Nexus 2022 conference.
RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
NCDs, Part III: Agency Mandates, Decisions, Coverage and Access
Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
Medicare Advantage, Part III: Performance Measures and STAR Ratings
Tune into the third episode in our video series focused on Medicare Advantage. In this segment, Avalere quality measures experts, Michael Lutz and Taylor Musser, discuss the shift toward member-reported measures and implications of recent measure reporting methodology updates.
Medicare Advantage, Part II: Influencing CMS Policy
Tune into the second episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Center for Medicaid and Medicare (CMS) employees Sean Creighton and Tom Kornfield discuss their thoughts on the best ways for health plans to influence CMS decision making, including timing of engagement and critical messaging elements.
Medicare Advantage, Part I: The Future of MA
Tune into the first episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Centers for Medicare & Medicaid Services (CMS) employees, Sean Creighton and Tom Kornfield, discuss the outlook for Medicare Advantage, factors that will influence growth of the program, and a behind-the-scenes look at CMS policymaking considerations.
NCDs, Part II: Evidence Development to Fulfill CED Requirements
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.
NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.